Ad is loading...
EATVX
Price
$44.38
Change
+$0.31 (+0.70%)
Updated
Nov 22 closing price
VVIAX
Price
$70.26
Change
+$0.54 (+0.77%)
Updated
Nov 22 closing price
Ad is loading...

EATVX vs VVIAX

Header iconEATVX vs VVIAX Comparison
Open Charts EATVX vs VVIAXBanner chart's image
Eaton Vance Tx-Mgd Value A
Price$44.38
Change+$0.31 (+0.70%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$70.26
Change+$0.54 (+0.77%)
VolumeN/A
CapitalizationN/A
EATVX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
EATVX vs. VVIAX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EATVX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. EATVX (826M). VVIAX pays higher dividends than EATVX: VVIAX (2.36) vs EATVX (0.64). EATVX was incepted earlier than VVIAX: EATVX (25 years) vs VVIAX (24 years). EATVX is a more actively managed with annual turnover of: 31.00 vs. VVIAX (10.00). EATVX has a lower initial minimum investment than VVIAX: EATVX (1000) vs VVIAX (3000). EATVX (26.13) and VVIAX (26.09) have marching annual gain over last year. VVIAX return over 5 years is better than : 53.09 vs. EATVX (47.52).
EATVXVVIAXEATVX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence25 years24 years-
Gain YTD20.87219.672106%
Front LoadN/AN/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRAN/AN/A-
Net Assets826M184B0%
Annual Yield % from dividends0.642.3627%
Returns for 1 year26.1326.09100%
Returns for 3 years11.6924.7747%
Returns for 5 years47.5253.0990%
Returns for 10 years78.00112.2669%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics